Karyopharm files for Chapter 11 to pursue Ayrmid merger
KPTI•KPTI•KPTI•KPTI•Karyopharm Therapeutics filed for Chapter 11 protection to pursue a merger with Ayrmid, which will serve as lead bidder in a court-supervised sale process. The company’s secured lenders committed up to $55 million in debtor-in-possession financing, subject to court approval, and the merger is expected to close in the first quarter of 2027.
Karyopharm Therapeutics filed for Chapter 11 protection in the Southern District of Texas to pursue a merger with Ayrmid. Ayrmid will serve as lead bidder in a court-supervised sale process that allows competing offers for the company’s assets.
Existing secured lenders committed up to $55 million in debtor-in-possession financing, subject to court approval. Karyopharm expects operations to continue uninterrupted during the restructuring, including advancement of its multiple myeloma and myelofibrosis programs. The merger is expected to close in the first quarter of 2027, subject to conditions in the Chapter 11 plan.
